Glaukos (GKOS) revenue breakdown
By product, Glaucoma is the largest at 83% of fiscal 2025 revenue; Corneal Health grew fastest, 56% a year over 6 years.
By region, United States is the largest at 74% of fiscal 2025 revenue; International grew fastest, 34% a year over 9 years.
Revenue by product
Fiscal years, as Glaukos reports them in its 10-K filings; fiscal 2025 total $507M.
| Products | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|
| Glaucoma | $231M | $179M | $232M | $214M | $237M | $303M | $421M | 83% |
| Corneal Health | $6M | $46M | $62M | $69M | $78M | $80M | $86M | 17% |
Revenue by region
Fiscal years, as Glaukos reports them in its 10-K filings; fiscal 2025 total $507M.
| Regions | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $105M | $141M | $152M | $192M | $173M | $224M | $203M | $219M | $270M | $375M | 74% |
| International | $9M | $18M | $30M | $45M | $52M | $70M | $80M | $95M | $113M | $132M | 26% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for GKOS.
Open GKOS in InvestinglyQuestions
Where does Glaukos make its money?
In fiscal 2025, by product: Glaucoma $421M, Corneal Health $86M.
From Glaukos's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.